Ocugen
OCGN · NASDAQ
Bulios Fair Price
$0.99
6.6% downside
Current Price
$1.06
According to Bulios Fair Price, OCGN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Ocugen (OCGN) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products. Its primary goal is to provide patients with high therapeutic value medicines and contribute to improving their health outcomes. The company specializes in the treatment of ocular diseases, including rare eye disorders. Ocugen stock is suitable for investors interested in the biotechnology sector and those who want to support innovative treatment approaches. Add Ocugen stock to your watchlist on Bulios and gain access to the latest information about this company that is pushing the boundaries of ocular disease management.
Sector
Healthcare
Industry
Biotechnology
CEO
Shankar Musunuri
Employees
116
Headquarters
Malvern
Upcoming events
Earnings
Upcoming earnings report